Skip to main content
TipRanks
Go Ultimate75% OFF

Siemens Healthineers AG (SEMHF) Q4 2026 Earnings Report

194 Followers

SEMHF Q4 2026 EPS Results

Actual EPS
$0.77
Consensus EPS
$0.75
Beat/Miss
Beat by +$0.02
One Year Ago EPS
$0.76

SEMHF Q4 2026 Revenue Results

Actual Revenue
$7.58B
Expected Revenue
$7.58B
Beat/Miss
Missed by -$6.67M
YoY Revenue Growth
+7.31%

Earnings Announcement Details

Quarter
Q4 2026
Date
11/05/2026
Time
Before Open
Conference Call
Thursday, November 5, 2026
SEMHF Upcoming Earnings

Siemens Healthineers AG's next earnings date is estimated for February 4, 2027, based on past reporting schedules.

Q4 2026 Earnings Call Audio

SEMHF Q4 2026 Earnings Call
0:00 / 0:00

Q4 2026 Earnings Slide Deck

Q4 2026 Earnings Call Summary

Q4 2026
Earnings Call Date:Nov 05, 2026|% Change Since:-4.43%|
Earnings Call Sentiment|Positive

The call was broadly positive, supported by strong synergetic core growth, robust equipment demand, solid fiscal 2026 execution, innovation momentum, strategic partnerships and continued cash generation. However, the company faces meaningful challenges from Diagnostics' revenue and margin decline, China market rebasing and pricing pressure, foreign exchange and inflation, the ultrasound wind-down, higher financing costs and substantial separation-related expenses. Management presented fiscal 2027 guidance as prudent and reiterated its medium-term ambition for double-digit adjusted EPS growth.

Company Guidance

For fiscal year 2027, Siemens Healthineers expects comparable revenue growth between 4% and 5%, including growth dilution of around 70 basis points from the partial exit in the ultrasound portfolio, and adjusted earnings per share of EUR 2.20 and EUR 2.40; Imaging is expected to deliver decent mid-single-digit growth more than 5%, Precision Therapy pretty much the middle between mid-single digit and high single digit, more than 6% to 7%, Diagnostics low to mid-double-digit margin expansion with revenue growth should stabilize, financial income, net between minus EUR 440 million and minus EUR 400 million, and a tax rate of 24% to 26%. The EPS bridge includes EUR 0.15 incremental headwind from inflation in the supply chain, on top of EUR 0.04, roughly EUR 0.20 of year-over-year headwinds from four other topics, and around EUR 50 million or around EUR 0.03 EPS from focusing the ultrasound portfolio, while the more prudent China assumption and the upside from foreign exchange be roughly a wash. For Q1, revenue growth is expected to be within the growth outlook for the full fiscal year, with Imaging around mid-single digits, Precision Therapy in the mid- to high single-digit range, and Diagnostics year-over-year flat revenue development; margins are expected to be flat year-over-year in Imaging, to decline in Precision Therapy in the same ballpark as the assumptions for the full fiscal year, and to show a low to mid-double-digit basis points margin expansion in Diagnostics. Medium term, the synergetic core is expected to grow between 6% and 9%, Imaging is expected to have margin expansion from scale, Precision Therapy is expected to expand margin by 100 basis points a year, Diagnostics retains its ambition to achieve mid-teens margins, and the EUR 400 million savings program is expected to run through 2030.

  • Strong Synergetic Core and Group GrowthThe synergetic core grew 8.1% in Q4 and 6.1% for fiscal 2026, fueled by healthy demand across geographies. Group revenue growth was 5.9% in Q4, with the Americas up 7%, Asia Pacific and Japan delivering double-digit growth, and EMEA growing 4%.
  • Healthy Equipment Demand and Order IntakeThe equipment book-to-bill ratio was 1.15 in Q4 and 1.14 for fiscal 2026. The company said momentum was particularly strong in the Americas and Asia Pacific and Japan, with Europe solid and the synergetic core in China stable at low levels.
  • Fiscal 2026 Results Met or Exceeded GuidanceGroup comparable growth was 4%, at the upper end of the amended guidance range. Adjusted EPS was EUR 2.42, slightly above the prior year and within the upper half of the outlook range. Excluding EUR 0.16 of tariff refunds and sizable negative Q4 one-offs, adjusted EPS was EUR 2.30, the midpoint of the initial EUR 2.20 to EUR 2.40 guidance range.
  • Stable Dividend ProposalThe company proposed a dividend of EUR 1 per share, fully in line with its stable-to-progressive dividend policy and representing a payout ratio of 50% of net income.
  • Quest Diagnostics Contract ExtensionDiagnostics extended its long-standing relationship with Quest Diagnostics by another 5 years. Management said the extension demonstrates customer trust in the Atellica platform, assay portfolio and automation offering.
  • Imaging Revenue GrowthImaging revenue grew 10% in Q4, supported by continued high growth in Photon-counting CT and the radiopharmaceutical business, as well as very strong growth in MR. Management said Imaging showed strong underlying conversion and a very strong underlying margin after considering stated headwinds and one-offs.
  • Precision Therapy and Varian GrowthPrecision Therapy delivered 7% growth in Q4, while Varian delivered more than 8% growth for the year. Management said the business continued to benefit from strong demand and described the Varian performance as another strong year.
  • Accela Radiation Therapy InnovationAccela was launched at ASTRO five weeks before the call and received overwhelmingly positive customer feedback. A highlighted case can be treated in 97 seconds of total beam-on time within only a few breath-holds, and breast cancer treatment can be delivered in a single breath-hold. The company expects European regulatory approval soon and expects to begin treating the first patients later in the calendar year.
  • Expansion of Strategic Value PartnershipsThe company has doubled orders and revenue in long-term strategic partnerships over the last 4 years. It has signed 222 value partnerships, including 12 during fiscal 2026, and signed new deals worth more than EUR 400 million in Q4.
  • Cash Generation and DeleveragingHealthineers reported a cash conversion rate between 0.8 and 0.9 over the last 3 years and average annual free cash flow of around EUR 2.5 billion. The company has continuously delevered since the Varian acquisition in 2021 and intends to continue until reaching a target range of around 2.5x net debt over EBITDA.
  • Continued Investment in InnovationManagement said the company funds breakthrough innovation organically, with R&D intensity among the highest in the industry and unmatched absolute R&D spending. Examples cited included Photon-counting CT and Optiq AI, a first-to-market AI algorithm intended to improve live imaging resolution during surgery.
  • Refinancing Preparation for Siemens DeconsolidationThe company has already refinanced 70% of its loan volume. Including the October refinancing, the pro forma average interest rate would be around 2.5% per annum. Healthineers also plans to secure bridge financing, operational financing and backup liquidity if Siemens AG terminates its loan.
  • Diagnostics Transformation and Margin AmbitionDiagnostics reiterated its ambition to achieve mid-teens margins over the medium term. Core Lab represents more than 60% of Diagnostics revenue, and Atellica contributes more than 70% of Core Lab revenue. The earlier transformation program lifted adjusted EBIT margin from 1% in 2023 to almost 8% at the end of 2025, and the company is targeting an additional EUR 400 million of savings.
  • Strategic Portfolio and Corporate ReshapingThe company initiated the Diagnostics carve-out with the intention of transitioning Diagnostics to a stand-alone market-leading in-vitro diagnostics pure play by mid-calendar year 2028. It is also preparing for deconsolidation from Siemens, a transition to the Healthineers brand, and a regional structure that moves the Middle East and Africa zone into the Asia Pacific and Japan region.
  • Transform4Future Productivity ProgramHealthineers launched Transform4Future to generate sustainable savings that will more than compensate for over EUR 300 million of stranded costs from the Diagnostics carve-out, focused ultrasound and Siemens deconsolidation by fiscal 2030. The program is expected to become P&L effective from fiscal 2028 through fiscal 2030.
  • Fiscal 2027 Revenue and EPS OutlookFor fiscal 2027, the company expects comparable revenue growth between 4% and 5% and adjusted EPS of EUR 2.20 to EUR 2.40. It expects Imaging growth of more than 5%, Precision Therapy growth of more than 6% to 7%, Diagnostics revenue growth to stabilize, and low- to mid-double-digit Diagnostics margin expansion.
  • Radiopharmaceutical Business ScaleManagement said the radiopharma business has grown to about EUR 1 billion, supported in part by the AAA acquisition and expansion into Europe. The company intends to focus on PET and SPECT imaging rather than vertically integrating into tracer discovery, development or therapeutic manufacturing.

SEMHF Earnings History

SEMHF earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Feb 04, 20272027 (Q1)0.56-0.55――
Nov 05, 20262026 (Q4)0.750.770.761.47% (+0.01)
Jul 31, 20262026 (Q3)0.590.780.719.38% (+0.07)
May 07, 20262026 (Q2)0.560.590.63-5.36% (-0.03)
Feb 05, 20262026 (Q1)0.500.550.57-3.92% (-0.02)
Nov 05, 20252025 (Q4)0.770.760.751.49% (+0.01)
Jul 30, 20252025 (Q3)0.590.710.5823.08% (+0.13)
May 07, 20252025 (Q2)0.630.630.611.82% (+0.01)
Feb 06, 20252025 (Q1)0.530.570.554.08% (+0.02)
Nov 06, 20242024 (Q4)0.720.750.6515.52% (+0.10)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed